charles baum m d m s facg ftos vice president and head u
play

Charles Baum, M.D., M.S., FACG, FTOS Vice President and Head U.S. - PowerPoint PPT Presentation

Charles Baum, M.D., M.S., FACG, FTOS Vice President and Head U.S. Medical Affairs Vice President and Head U.S. Medical Affairs Takeda Pharmaceuticals International 1 Recognizing Obesity as a Disease Obesity recognized as a disease -


  1. Charles Baum, M.D., M.S., FACG, FTOS Vice President and Head U.S. Medical Affairs Vice President and Head U.S. Medical Affairs Takeda Pharmaceuticals International 1

  2. Recognizing Obesity as a Disease • Obesity recognized as a disease - American Medical Association (June 2013) Ob Obesity Guidelines/Position Statements it G id li /P iti St t t AACE Surgery Surgery ENDO/TOS ACP VA/D D VA/DoD AGA Pharmacotherapy Pharmacotherapy Lifestyle Modification Lifestyle Modification Lifestyle Modification Lifestyle Modification Diet Diet Physical Activity Physical Activity 2

  3. Multifaceted Medical Weight Loss Approaches Are Most Effective Approaches Are Most Effective • In a randomized clinical trial of obese patients, those subjects who received combination therapy lost more weight than subjects undergoing a structured lifestyle intervention or pharmacotherapy alone 1 i i h h l 1 Pharmacotherapy alone (n=45) Structured Lifestyle Intervention alone (n=47) 0 Combined Therapy (pharmacotherapy + Structured lifestyle Intervention) (n=49) 2 4 4 g Weight Loss, kg 6 8 10 W 12 14 16 0 3 6 10 52 18 40 Weeks • Another randomized controlled prospective study found significantly greater mean weight loss with pharmacotherapy plus lifestyle intervention after 1 year and 4 years compared with lifestyle intervention alone (p<0 001) 2 compared with lifestyle intervention alone (p<0.001) 2 1. Wadden et al, N Engl J Med 2005; 353:2111-20 (adapted with permission) 3 2. Torgerson et al, Diabetes Care 2004;27:155-61

  4. New Approaches to Obesity Pharmacotherapy : Designed to maximize weight loss, maintenance, g g , , program adherence, access & affordability • Safe and effective for both weight loss induction and weight maintenance including novel dosing Product regimens • Evidence for improvement in clinical outcomes and overall cost • Evidence-based lifestyle/BMOD program results in y p g Program additive effects on weight loss and adherence • Program is integrated into benefits design • Sustainable • Voucher programs insure affordable pricing Affordable • Reliable price with progressive savings at retail pharmacy (behavioral economics) Access • Novel payer partnerships such as risk-based contracting are needed to enhance coverage

  5. Digital technology expands reach and allows for personalized tailoring: The ScaleDown approach • Results − Higher engagement, lower recidivism with lower intensity − Comparable weight loss as seen with f face to face lifestyle management t f lif t l t programs DPP Look Ahead ScaleDown Weight loss 7% 5% 7% > 5% weight loss at 50% 43% 43% 6 months Face to face 16 28 1 sessions 5

  6. Comprehensive Community Approaches to Obesity Individuals, Families, Communities, Society Schools Businesses Faith-Based Initiatives ics l Economi Mess Med Physical Physical dia Behaviora Healthy ages Activity Food Opport. Environment B Healthcare Systems Obesity Treatment 6 Baum C. Pharmacoeconomics. 2015 Feb 17. [Epub]

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend